Literature DB >> 7903965

Multidrug resistance in rat colon carcinoma cell lines CC531, CC531mdr+ and CC531rev.

E Gheuens1, S van der Heyden, H Elst, A Eggermont, A Van Oosterom, E De Bruijn.   

Abstract

A rat colon carcinoma cell line, CC531, was exposed to stepwise increasing concentrations of colchicine. A cell line, CC531mdr+, which grows in the presence of 0.2 microM of colchicine was obtained. A revertant cell line, CC531rev was isolated upon colchicine withdrawal. The CC531mdr+ displayed a multidrug-resistant phenotype. Marked resistance to the selecting agent colchicine, was found (RF = 37.5) as well as to vinblastine (RF = 11.3) and actinomycin D (RF = 2.6). Cross resistance to doxorubicin (RF = 8) and daunorubicin (RF = 13.3) was demonstrated. Verapamil was able to reverse drug resistance to colchicine and daunorubicin. The revertant cell line, CC531rev, showed increased sensitivity to colchicine (RF = 0.43), vinblastine (RF = 0.13), doxorubicin (RF = 0.28) and daunorubicin (RF = 0.56). Marked cross resistance to cis-platinum (RF = 6.9) was also induced in CC531mdr+ and was maintained in CC531rev. We conclude that CC531 displays an intrinsic low-level multidrug-resistant phenotype, which was amplified in the CC531mdr+ variant. This correlates with a higher level of expression of P-glycoprotein. CC531rev lacks the multidrug-resistant phenotype and can be used as the drug-sensitive counterpart of the latter two cell lines. Furthermore, it has been shown that in these cell lines cis-platinum resistance is mediated through a mechanism independent of the multidrug-resistant phenotype, since the revertant cell line CC531rev has lost the multidrug-resistant phenotype while retaining the concomitantly induced cis-platinum resistance of the multidrug-resistant variant CC531mdr+.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7903965      PMCID: PMC5919088          DOI: 10.1111/j.1349-7006.1993.tb02822.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  47 in total

1.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies.

Authors:  H Hamada; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

2.  ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.

Authors:  M Naito; H Hamada; T Tsuruo
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

3.  Isolation of highly multidrug-resistant P388 cells from drug-sensitive P388/S cells by flow cytometric cell sorting.

Authors:  D D Ross; J V Ordóñez; C C Joneckis; J R Testa; B W Thompson
Journal:  Cytometry       Date:  1988-07

4.  Combined treatment of colon adenocarcinoma in rats with tumor necrosis factor and the interferon inducer ABPP.

Authors:  R L Marquet; A M Eggermont; R W de Bruin; W Fiers; J Jeekel
Journal:  J Interferon Res       Date:  1988-06

5.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

6.  Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

Authors:  D R Bell; J H Gerlach; N Kartner; R N Buick; V Ling
Journal:  J Clin Oncol       Date:  1985-03       Impact factor: 44.544

7.  Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells.

Authors:  A R Safa; C J Glover; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1986-05-15       Impact factor: 5.157

8.  Effects of verapamil on in vitro intracellular accumulation and retention of daunorubicin in blast cells from patients with acute nonlymphocytic leukemia.

Authors:  D D Ross; C C Joneckis; C A Schiffer
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

9.  Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.

Authors:  H Herweijer; P Sonneveld; F Baas; K Nooter
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

10.  Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

View more
  6 in total

1.  Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model.

Authors:  W Van de Vrie; J H Schellens; W J Loss; H J Kolker; J Verwey; G Stoter; N M Durante; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

2.  Cyclosporin A enhances locoregional metastasis of the CC531 rat colon tumour.

Authors:  W Van de Vrie; R L Marquet; A M Eggermont
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.

Authors:  W Van de Vrie; S A Van der Heyden; E E Gheuens; A M Bijma; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

4.  Hypotonic cell swelling stimulates permeability to cAMP in a rat colonic cell line.

Authors:  P E Golstein; A Daifi; R Crutzen; A Boom; W Van Driessche; R Beauwens
Journal:  Pflugers Arch       Date:  2004-01-16       Impact factor: 3.657

5.  Lack of correlation between mdr-1 expression and volume-activation of cloride-currents in rat colon cancer cells.

Authors:  C De Greef; S van der Heyden; F Viana; J Eggermont; E A De Bruijn; L Raeymaekers; G Droogmans; B Nilius
Journal:  Pflugers Arch       Date:  1995-06       Impact factor: 3.657

6.  5'-Deoxy-5-fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression.

Authors:  S van der Heyden; E Gheuens; W van de Vrie; D Van Bockstaele; A Van Oosterom; A Eggermont; E A De Bruijn
Journal:  Jpn J Cancer Res       Date:  1994-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.